• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Lumiracoxib

Lumiracoxib

Product ID L8248
Cas No. 220991-20-8
Purity ≥98%
Product Unit SizeCostQuantityStock
25 mg $67.80 In stock
100 mg $183.10 In stock
250 mg $352.30 In stock
1 g $1,070.70 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Lumiracoxib is a non-steroidal anti-inflammatory drug (NSAID) that acts as an inhibitor of COX enzymes with specificity for COX-2. Like other NSAIDs, lumiracoxib exhibits anti-inflammatory, analgesic, antipyretic, and antinociceptive activities. In animal models of metabolic syndrome, lumiracoxib reverses vascular remodeling and inflammation. In animal models with experimental autoimmune encephalitis (EAE, a translational model of multiple sclerosis), lumiracoxib inhibits lymphocyte responses and decreases disease severity; in similar in vitro models, lumiracoxib inhibits T cell proliferation and modulates expression of T-bet, IL-10, and IFN-γ. This compound may also inhibit thromboxane receptors. Additionally, lumiracoxib exhibits some anticancer potential, inducing G0/G1 cell cycle arrest and apoptosis and inhibiting proliferation in non-small cell lung cancer (NSCLC) cell lines.

Product Info

Cas No.

220991-20-8

Purity

≥98%

Formula

C15H13ClFNO2

Formula Wt.

293.72

Chemical Name

2-[(2-Chloro-6-fluorophenyl)amino]-5-methylbenzeneacetic acid

IUPAC Name

2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid

Melting Point

158-159°C

Appearance

Pale Yellow Crystal

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

L8248 MSDS PDF

Info Sheet

L8248 Info Sheet PDF

References

Windsor MA, Valk PL, Xu S, et al. Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib. Bioorg Med Chem Lett. 2013 Nov 1;23(21):5860-4. PMID: 24060487.

Renna NF, Diez ER, Lembo C, et al. Role of Cox-2 in vascular inflammation: an experimental model of metabolic syndrome. Mediators Inflamm. 2013;2013:513251. PMID: 23476105.

Hao JQ, Li Q, Xu SP, et al. Effect of lumiracoxib on proliferation and apoptosis of human nonsmall cell lung cancer cells in vitro. Chin Med J (Engl). 2008 Apr 5;121(7):602-7. PMID: 18466679.

Selg E, Buccellati C, Andersson M, et al. Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol. 2007 Dec;152(8):1185-95. Erratum in: Br J Pharmacol. 2008 Apr;153(8):1763. Ambrosio, E [corrected to Ambrosio, M]. PMID: 17965743.

Ni J, Shu YY, Zhu YN, et al. COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. J Neuroimmunol. 2007 May;186(1-2):94-103. PMID: 17442406.

Esser R, Berry C, Du Z, et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol. 2005 Feb;144(4):538-50. PMID: 15655513.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • D1644

    Deltorphin I

    Opioid peptide; δOR agonist.

    ≥98%
  • A5032

    D,L-Aminoglutethimide

    Aromatase inhibitor.

    ≥98%
  • R6052

    Recombinant Mycoplasma Pneumonia Antigen

    Pneumonia antigen

  • K0053

    Kanamycin A Monosulfate

    Aminoglycoside; protein translation inhibitor, ...

    ≥98%
  • H2980

    Humanin, human

    Endogenous peptide; FPRL1/2 agonist.

    ≥95%
  • T3100

    Thyrotropin-releasing Hormone

    Endogenous tripeptide, involved in HPA signalin...

    ≥95%
  • E5200

    Enalaprilat Dihydrate

    Enalapril metabolite; ACE inhibitor.

    ≥98%
  • C3578

    L-Citrulline

    Byproduct of L-arginine metabolism found in wat...

    ≥98%
  • B4796

    BLZ-945

    CSF-1R Inhibitor.

    ≥95%
  • P691320

    PRI-724

    Wnt/beta-catenin/CBP inhibitor

    ≥98%
  • S0278

    Satraplatin

    Pt-based DNA cross-linker.

    ≥98%
  • C9882

    Cytochalasin E

    Mycotoxin produced by Aspergillus; actin polyme...

    ≥98%
  • H1794

    Hexamethonium Bromide Hydrate

    Non-depolarizing NMJ blocker; nAChR antagonist....

    ≥98%
  • T0105

    Taxol C

    Taxane synthesis intermediate.

    ≥95%
  • C4000

    CK-636

    Arp2/3 inhibitor.

    ≥98%
  • A9814

    AZD-4547

    FGFR inhibitor.

    ≥98%
  • T3202

    Tianeptine

    μOR and δOR agonist, D2/D3 DA potentiator.

    ≥98%
  • G4484

    Glucagon-like Peptide II, rat

    Endogenous peptide hormone, involved in intesti...

    ≥95%
  • A4606

    Albendazole

    Benzimidazole; microtubule polymerization inhib...

    ≥95%
  • S6019

    Speract

    Peptide, derived from egg outer envelope; K+ ch...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only